74 results
Page 2 of 4
8-K
EX-99.1
bkp4t0u2libwtict
15 Mar 22
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
7:04am
8-K
EX-99.1
9m5gw4aewenfhgfva
10 Nov 21
Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
4:05pm
8-K
EX-99.1
em7g3paf9 lbt
5 Aug 21
Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates
5:31pm
8-K
EX-99.1
8n75shjxs54
13 May 21
Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates
7:34am
8-K
EX-99.1
xf4zf3650vna7 l7ia
29 Mar 21
Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates
5:26pm
8-K
EX-99.1
qljohu0p4 jga84lv
16 Nov 20
Windtree Therapeutics Reports Third Quarter 2020
7:40am
8-K
EX-99.1
yx130k
1 Oct 20
Windtree Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients
7:36am
8-K
EX-99.1
uc6tso6ixjrf4u
29 Sep 20
Other Events
7:37am
8-K
EX-99.1
zjv721
14 Aug 20
Windtree Therapeutics Reports Second Quarter 2020 Financial Results and Provides Key Business Updates
6:07am
8-K
EX-99.2
8fwxq9vf3sb 7gs26jfe
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
8-K
EX-99.1
ggi5hlpy1 4y2nv
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
424B4
s6c6k 5n5lddv
21 May 20
Prospectus supplement with pricing info
6:04am
8-K
EX-99.1
kgzvdxuiydwixepit40
14 May 20
Windtree Therapeutics Reports First Quarter 2020 Financial Results and Provides Key Business Updates
8:12am
S-1/A
45t9gv rggx
6 May 20
IPO registration (amended)
5:31pm